We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER /HER2– Locally Advanced Breast Cancer: Integrated Analysis of <sup>18</sup>F-FES PET-CT and Metabolites with Treatment Response.
- Authors
Shao, Qing; Zhang, Ningning; Pan, Xianjun; Zhou, Wenqi; Wang, Yali; Chen, Xiaoliang; Wu, Jing; Zeng, Xiaohua
- Abstract
Purpose: This Phase II trial was objected to evaluate the efficacy and safety of adding fulvestrant to neoadjuvant chemotherapy in patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)– locally advanced breast cancer (LABC). Additionally, the study aimed to investigate the association of 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) positron emission tomography (PET)–computed tomography (CT) and metabolites with efficacy. Materials and Methods: Fulvestrant and EC-T regimen were given to ER+/HER2– LABC patients before surgery. At baseline, patients received 18F-FES PET-CT scan, and plasma samples were taken for liquid chromatography–mass spectrometry analysis. The primary endpoint was objective response rate (ORR). Secondary endpoints included total pathologic complete response (tpCR) and safety. Results: Among the 36 patients enrolled, the ORR was 86.1%, the tpCR rate was 8.3%. The incidence of grade ≥ 3 treatment-emergent adverse events was 22%. The decrease in ER value in sensitive patients was larger than that in non-sensitive patients, as was Ki-67 (p < 0.05). The maximum standardized uptake value, mean standardized uptake values, total lesion ER expression of 18F-FES PET-CT in sensitive patients were significantly higher than those in non-sensitive patients (p < 0.05). Moreover, these parameters were significantly correlated with Miller and Payne grade and the change in ER expression before and after treatment (p < 0.05). Thirteen differential expressed metabolites were identified, which were markedly enriched in 19 metabolic pathways. Conclusion: This regimen demonstrated acceptable toxicity and encouraging antitumor efficacy. 18F-FES PET-CT might serve as a tool to predict the effectiveness of this therapy. Altered metabolites or metabolic pathways might be associated with treatment response.
- Subjects
EPIDERMAL growth factor receptors; POSITRON emission tomography computed tomography; POSITRON emission tomography; PATHOLOGIC complete response; METASTATIC breast cancer
- Publication
Cancer Research & Treatment, 2025, Vol 57, Issue 1, p126
- ISSN
1598-2998
- Publication type
Academic Journal
- DOI
10.4143/crt.2023.1251